DiNapoli honored by Best Lawyers in America based on peer-review surveys
New York: Kaye Scholer today announced that IP Litigation and Life Sciences partner Daniel DiNapoli was just named “2012 New York City Biotechnology Law Lawyer of the Year” by Best Lawyers, the oldest legal peer-review publication in the nation.
Best Lawyers compiles its lists of outstanding attorneys by conducting exhaustive peer-review surveys in which thousands of leading lawyers confidentially evaluate their professional peers. The current, 18th edition of The Best Lawyers in America (2012) is based on more than 3.9 million detailed evaluations of lawyers by other lawyers. The publication also issues an annual Best Law Firms in America guide based on practice area and the overall number of attorneys ranked in Best Lawyers in partnership with U.S. News & World Report.
Only a single lawyer in high-profile legal specialties in large legal communities is recognized as the “Lawyer of the Year.” DiNapoli received particularly high ratings in the Best Lawyers survey by based on his peers’ assessment of his abilities, professionalism, and integrity. Steven Naifeh, President of Best Lawyers, says, “We continue to believe – as we have believed for more than 25 years – that recognition by one’s peers is the most meaningful form of praise in the legal profession. We congratulate Dan DiNapoli on being selected as the ‘New York City Best Lawyers Biotechnology Law Lawyer of the Year’ for 2012.”
DiNapoli concentrates his practice in patent, trade secret, and unfair competition litigation and counseling with a emphasis on biotechnology, pharmaceuticals, ANDA litigations, medical diagnostics, and surgical devices. He has represented leading research-based pharmaceutical and biotechnology companies, such as Pfizer Inc and Chiron Corporation (now part of Novartis), in all aspects of complex patent litigations. His experience includes patent infringement actions concerning antibiotics, anti-hypertensive drugs, antifungal drugs, treatments for erectile dysfunction, treatments for bacterial infections, anti-clotting drugs, pharmaceutical formulations, the cloning of alpha-interferon, the cloning of rennet, monoclonal antibodies, surgical devices, and methods for producing transgenic mice.
DiNapoli’s experience also includes litigation against generic drug manufacturers under the Hatch-Waxman Act. Indeed, DiNapoli and Partner Aaron Stiefel recently made headlines when they successfully defended Pfizer’s Viagra patent from being infringed by a generic manufacturer. In Pfizer v. Teva Pharmaecuticals, the Kaye Scholer team successfully secured a victory that preserves Pfizer’s exclusivity to the Viagra compound patent for an additional seven years until 2019.
Kaye Scholer’s 58-lawyer, multidisciplinary Life Sciences group represents the world’s biggest companies in the pharmaceutical market, as well as emerging biotech and medical device entities, drawing on its significant experience in Antitrust, Patent Litigation, Product Liability, White-Collar Litigation and Investigations, Compliance Counseling and Corporate M&A. The 2011 Legal 500 recently named us one of the top five law firms in the nation for Life Sciences, while 2011 Chambers USA named us among the top six firms for our understanding of the key issues confronting the life sciences industry.
About Kaye Scholer LLP
Founded in New York in 1917, Kaye Scholer combines the continuity and business acumen of a century-old law firm with a forward-looking, tech savvy, results-driven approach focused around lasting client relationships. With industry strengths in life sciences, financial services, technology, real estate and energy & infrastructure, Kaye Scholer offers strategic guidance and legal services to public and private entities facing litigation, transactional or governance challenges. Kaye Scholer’s lawyers regularly advise on matters across multiple legal jurisdictions, including in the US, Canada, UK, EU, China and Japan.
# # #
PR & Communications Manager Kaye Scholer
Also of Interest
- Shape of Things to Come: Protecting Product Configuration and Packaging Design September 26, 2016 • Articles
- On the Road to a Safe and Secure Internet of Things: What Companies Should Do September 19, 2016 • Articles
- Arbisser Featured in The Recorder and Law360... September 7, 2016 • Media Mentions
- Consumer Products: Adapting to Innovation Fall 2016 • Reports / Newsletters
- ILS and Zinsser Analytic Shareholders Sell to Gardner Denver Medical September 2, 2016 • Client Successes
- Kaye Scholer Advises Veracen on Merger of Equals with Turner Investments August 31, 2016 • Client Successes
- UNITED STATES: Trade Facilitation and Trade Enforcement Act of 2015 Strengthens... August 23, 2016 • Articles
- UNITED STATES: Phantom Mark Depicting Arrangement of Numerical Financial Data... August 23, 2016 • Articles
- Daily Journal Names Malecek Among the “Top 75 Intellectual Property Litigators” August 17, 2016 • Recognitions